**
U.S. generic drugmaker Akorn < AKRX.O > is taking former suitor Fresenius to court after the German healthcare group cancelled their $ 4.75 billion takeover agreement.
FRANKFURT (Reuters)-
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $ 4.75 billion takeover agreement.
FRANKFURT
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $ 4.75 billion takeover agreement.
FRANKFURT
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $ 4.75 billion (3.4 billion pounds) takeover agreement.
Akorn — German drugmaker Fresenius pulled out its $ 4.75 billion deal to buy
the U.S. generic drugmaker, saying it had found «material breaches» of Food and Drug Administration data integrity requirements at Akorn.
German health - care group Fresenius said it had decided to pull out of its planned acquisition of Akorn after it found data integrity breaches at
the U.S. generic drugmaker.